QPPV.COM KNOWLEDGE ASSESSMENT

Drug-Induced Pulmonary Toxicity: Respiratory Safety Assessment in Clinical Development and Pharmacovigilance

Test your understanding of the concepts covered by Drug-Induced Pulmonary Toxicity: Respiratory Safety Assessment in Clinical Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should serial imaging be reviewed in a potential pulmonary toxicity case?

A single follow-up scan determines causality with certainty Comparison of baseline, onset, maximum abnormality and follow-up can clarify chronology and evolution Serial imaging is required only for bronchospasm Follow-up imaging eliminates the need to evaluate competing diagnoses

Question 2 of 10 Which additional assessment is most directly useful when wheezing and suspected drug-related airway obstruction are reported?

Spirometry, including consideration of bronchodilator response Serial DLCO alone Natriuretic peptide testing alone Bronchoscopy in every case

Question 3 of 10 A patient has progressive exertional dyspnea, restrictive physiology and serially worsening reticulation on CT after prolonged treatment. Which phenotype is most directly suggested?

Respiratory depression Pulmonary fibrosis Acute bronchospasm Isolated pulmonary edema

Question 4 of 10 What is the appropriate professional approach to rechallenge when a serious pulmonary reaction is suspected?

Intentional rechallenge should routinely be performed to confirm causality Rechallenge is generally inappropriate for serious suspected pulmonary reactions, although inadvertent or clinically necessary re-exposure may provide evidence A negative rechallenge always excludes drug causality Rechallenge is required before a case can be considered serious

Question 5 of 10 Why does improvement after treatment withdrawal not, by itself, prove drug causality?

Dechallenge has no value in pulmonary safety assessment Improvement may reflect natural disease progression, concomitant corticosteroids, delayed drug elimination or other interventions Pulmonary toxicity cannot improve after treatment withdrawal Dechallenge is valid only when the patient was not receiving any other treatment

Question 6 of 10 Which statement correctly compares pulmonary safety assessment with liver safety assessment?

Pulmonary safety has a universally accepted threshold equivalent to Hy's Law Pulmonary causality is normally established by a single oxygen-saturation value Pulmonary assessment is strongly phenotype-driven and generally lacks one universal population-level threshold equivalent to Hy's Law Pulmonary safety does not require assessment of competing causes

Question 7 of 10 A patient receiving immunosuppressive therapy develops fever, hypoxemia and bilateral infiltrates. A clinically relevant respiratory pathogen is identified. How should this evidence be handled?

The event must still be labelled drug-induced because it occurred during treatment The positive microbiology is a strong competing explanation that must be incorporated into causality assessment The infection result should be disregarded if CT shows ground-glass opacity The case should be considered unrelated to treatment without reviewing any other evidence

Question 8 of 10 Which exposure-history element is especially important when evaluating unexplained ILD?

Only the investigational product dose Occupational and environmental exposures such as dust, mold, birds, chemicals, smoking and vaping Only the patient's history of seasonal allergies Only exposure to medicines administered intravenously

Question 9 of 10 Which statement best describes the role of bronchoalveolar lavage in suspected drug-induced pulmonary toxicity?

BAL findings are usually pathognomonic for drug-induced lung injury BAL can help investigate infection, hemorrhage, malignancy and inflammatory patterns but is generally supportive BAL is mandatory before any pulmonary safety case can be assessed A normal BAL excludes all forms of pulmonary toxicity

Question 10 of 10 Which statement best distinguishes functional pulmonary toxicity from structural pulmonary injury?

Functional abnormalities and structural abnormalities always appear at the same time A normal chest CT excludes clinically relevant pulmonary toxicity Functional impairment may precede visible structural disease, and imaging abnormalities may occur despite relatively preserved spirometry Structural pulmonary injury is present only when oxygen saturation is reduced

Drug-Induced Pulmonary Toxicity: Respiratory Safety Assessment in Clinical Development and Pharmacovigilance

Cookie Settings